>
NeOnc Technologies Holdings, Inc.: Focused on Development of Innovative Drug Delivery Solutions for Brain Cancer and CNS Treatment
Publication Date: January 5, 2025
Published By: Life Sciencess Magazine
Article Link: https://thelifesciencesmagazine.com/neonc-technologies-holdings-inc/
For decades, treating brain cancer and central nervous system (CNS) disorders has been one of medicine’s toughest battles, largely because of the blood-brain barrier (BBB)—a natural defense that blocks most therapies from reaching the brain. While this barrier protects the brain, it also limits treatment options, leaving patients with few solutions and diminished hope. Today, advancements in biotechnology are changing that narrative, opening doors to non-invasive, targeted therapies that can overcome these limitations and deliver life-changing results.
NeOnc Technologies Holdings, Inc., is a clinical-stage life-sciences company focused on the development of innovative solutions for how we approach CNS diseases and brain cancer. Focused on the development of its innovative NEO-100 intranasal delivery platform, NeOnc Technologies is involved in the development of a method designed to bypass the BBB so that therapies reach the brain where they are needed most. NeOnc Technologies’s commitment is to deliver hope through innovation and work towards offering solutions that are effective and life-changing.
The Visionary Beginnings of NeOnc Technologies
NeOnc Technologies was founded on the visionary work of Dr. Chen, Founder, and Scientist, whose deep expertise in oncology and neuroscience led to a mission to solve one of medicine’s greatest challenges: delivering effective therapies across the blood-brain barrier. Dr. Chen’s research at USC Keck Medical School highlighted the potential to address critical unmet needs for patients with CNS diseases and brain cancer. This dedication to innovation continues to drive NeOnc Technologies’s mission to develop life-changing solutions and to offer hope where few treatment options exist.
Overcoming the Blood-Brain Barrier
The blood-brain barrier (BBB) presents a significant challenge for traditional therapies, as its selective nature prevents many treatments from reaching the brain in effective concentrations. This limitation has made it difficult to address brain disorders with conventional methods, reducing their overall effectiveness. NeOnc Technologies has responded to this issue with NEO-100, a development-stage platform that designed to bypasses the BBB safely, allowing therapeutic agents to reach their targets in the brain.
NEO-100 is made from a proprietary synthesis of Perillyl Alcohol (POH), which research suggests may have beneficial effects for treating CNS diseases. These include.
Potentially acting as a regulator for neurological pathways associated with tumor cell growth. When delivered intranasally, its small molecular size allows it to bypass the BBB. When delivered intra-arterially, it can temporarily open the BBB, allowing larger molecule therapeutics to pass through.
In high concentrations, NEO-100 may be a treatment for brain cancers.
In lower concentrations, it may serve as a solvent for traditional large-molecule therapeutics, potentially helping them cross the BBB.
It may potentially be conjugated with other CNS therapeutics to create compound formulations that may be used to enhance BBB penetration and improve brain cancer treatment.
With its first-mover advantage and a strong intellectual property protfolio protecting its innovation, NeOnc Technologies Holding, Inc. is paving the way for potentially new treatment options that were once thought impossible.
NeOnc Technologies’s Progress in Clinical Trials
NeOnc Technologies is making significant progress with its innovative therapies in clinical trials, advancing toward potential solutions for brain cancer and CNS disorders. The company’s commitment to groundbreaking research is demonstrated by ongoing Phase I and Phase II trials that are paving the way for new treatment options for patients.